increase the occurrence of cooperative mutations. The wholegenome sequencing of NPMc þ versus NPMc þ /FLT3-ITD leukaemia should help in verifying these alternative hypotheses. Regardless, the NPMc þ and NPMc þ /FLT3-ITD mice represent ideal models of human AMLs to study the mechanism of leukaemogenesis and test innovative therapeutic approaches.
Different mechanisms contribute to the inhibition of cellular immunity, for example, constitutive activation of the Jak/Stat pathway, loss of the T cell receptor repertoire complexity, deregulated expression of immunosuppressive cytokines and immune regulatory proteins such as CTLA-4, FasL and programmed cell death protein 1 (PD-1) ligands, that is, PD-L1 and PD-L2. 2 The major role of the PD-1 pathway is not at the initial T cell activation stage, but rather to regulate effector T cell responses in tissues by downregulating the activity of T cells in order to limit collateral tissue damage.
3 Accordingly, PD-1 þ tumor-infiltrating lymphocytes are inhibited by PD-L1 expressed by cancerous cells or other cells in the tumor microenvironment. In two recent clinical trials, antibody-mediated blockade of either PD-1 or PD-L1 resulted in outstanding clinical responses. 4, 5 Remarkably, an association between response and PD-L1 expression on tumor cells was observed.
Transformed cells of advanced CTCL are characterized by an exalted PD-L1 expression. This observation may be due to the STAT3-mediated activation of the PD-L1 gene, as STAT3 is expressed by CTCL, particularly strong at the advanced stage of Accepted article preview online 18 April 2013; advance online publication, 10 May 2013 the disease. Thus, PD-L1-mediated inhibition of immune response is suggested to be critical in the advanced stages of CTCL. 6 We recently identified and characterized spontaneously occurring PD-L1-specific, cytotoxic T cells. 7 In detail, CD8
þ PD-L1-specific T cells were isolated from peripheral blood of both melanoma patients and, albeit to a lesser extent, healthy donors; a PD-L1-derived HLA-A2-restricted epitope PD-L1 15-23 (LLNAFTVTV) was identified. PD-L1-specific T cells not only recognized and killed melanoma cells, but additionally PD-L1-expressing dendritic cells in a PD-L1-dependent manner.
Prompted by the high expression of PD-L1 in advanced, transformed CTCL, we scrutinized if these tumor cells also could be killed by PD-L1-specific T cells. The cytolytic function of the PD-L1-specific T cells was confirmed in standard 51 Cr-release assays using TAP-deficient T2 cells pulsed with PD-L1 15-23 ( Figure 1a) ; more importantly, these cells also lysed CTCL cell lines depending on their respective PD-L1 expression (Figures 1b and c) . In this regard, two CTCL lines, that is, Mac-1 and Mac-2a, which were established 8 from a HLA-A2-positive CTCL patient over the course of disease either from a skin biopsy (Mac-2a) or from circulating leukemic cells (Mac-1), were used as target cells. Although Mac-1 cells were efficiently killed by PD-L1-specific T cells, Mac-2a was not. Notably, analysis of PD-L1 expression of Mac-1 revealed a high expression by the leukemic CTCL cells, whereas the MAC-2a derived from a skin lesion did not express PD-L1 (Figure 1c ). Our observations on one hand indicate that the immune system is able to react to immune escape mechanisms of cancerous cells, and on the other hand suggest that inducing/boosting of cytotoxic T cell responses against PD-L1 is an attractive strategy to treat cancer, including advanced CTCL. The first notion is corroborated by the observation that the immune system is able to specifically recognize additional immune regulatory proteins, for example, indoleamine 2,3-dioxygenase (IDO), IDO-2 and FoxP3, and to kill immunosuppressive cells expressing such targets. [9] [10] [11] The second notion is supported by the success of other immunotherapies addressing the PD-1 pathway. 4, 5 In addition, we have previously described that the presence of IDO-specific CD8( þ ) T cells boosted T cell immunity against tumor-associated antigens by eliminating the suppressive cells. 12 
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1 CML-CP is leukemia stem cells (LSCs)-derived but leukemia progenitor cell (LPCs)-driven disease. In CML-CP patients ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, may induce complete cytogenetic or even molecular responses (CCR and CMR, respectively), but it is unlikely that they will cure CML. 2 One of the major reasons of that are BCR-ABL1 tyrosine kinase mutations. 3 These TKI-resistant BCR-ABL1 kinase isoforms usually result from point mutations in the fragment encoding the kinase domain, and numerous strategies have been tested to avoid and overcome the resistance. 4 Pre-existing and acquired point mutations in BCR-ABL1 kinase are detected in B23% of imatinib-naive and 50-90% of imatinibresistant CML-CP patients, respectively. 3 Moreover, BCR-ABL1 kinase mutants resistant to second-and third-generation TKIs emerged, for example due to new and/or compound mutations. 5, 6 Thus, CML cells are elusive targets even for the most advanced TKI therapies due to continuous accumulation of point mutations in BCR-ABL1 kinase, which encode the resistance to next generations of TKIs. 7 Point mutations usually result from misrepair/lack of repair of enhanced oxidative DNA damage arising from reactive oxygen species (ROS). 8 The potential role of ROS-induced oxidative DNA damage in accumulation of point mutations in CML-CP cells was highlighted by our previous studies, showing that not only imatinib-naive but also imatinib-treated LSCs and/or LPCs from CML-CP patients and CML-CP-like BCR-ABL1 transgenic mice contained 2-6 times more ROS and oxidized bases in comparison with their normal counterparts. 9, 10 In addition, anti-oxidants such as vitamin E reduced ROS and accumulation of TKI-resistant BRC-ABL1 kinase mutations in vitro.
11
To determine whether anti-oxidants may have clinical application, NSG mice were injected with CD34 þ cells obtained from five CML-CP patients with no detectable colonies carrying TKI-resistant mutations. These mice were either untreated or /SzJ (NSG) mice (Jackson Laboratory) were untreated (white bars) or treated with B400 international units of vitamin E ((±)-a-Tocopherol (Sigma)) per kilogram of body mass (gray bars) for 1 week. ROS was measured by dichlorofluorescin diacetate (DCFDA) fluorescence in bone marrow cells (BMC) and splenocytes (SPL) as described before; 9 *P ¼ 0.023, **Po0.001. (b) NSG mice were treated with 25 mg/kg busulfan (Sigma) 30 h before intravenous injection of 0.5 Â 10 6 CD34 þ cells from freshly diagnosed CML-CP patients. Vitamin E was administered daily by oral gavage for 12 weeks. Human cells were detected in total BMC SPL populations by flow cytometry using AmCyan-1-conjugated antihuman CD45 antibody (BD Pharmingen). Figure 1b were incubated with 1 mM imatinib, or left untreated, for 7 days in the absence of growth factors, and then plated in methylcellulose (MethoCult, Stem Cell Technologies) in the presence of 100 ng/ml stem cell factor, 100 ng/ml Flt-3 ligand, 20 ng/ml interleukin 3, 20 ng/ml granulocyte-colony-stimulating factor and 20 ng/ml interleukin 6. Total colonies/mouse and imatinib-resistant colonies were detected and calculated after 7 days. BCR-ABL1 kinase from imatinibresistant colonies was amplified by reverse transcription-PCR and sequenced as described before.
11 Vitamin E treatment inhibited the appearance of imatinib-resistant colonies; P ¼ 0.002, Student's t-test.
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